Navigation Links
Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Date:9/14/2009

e kidney, the five-year survival rate is 60 to 70 percent; but the survival rate is considerably lower after the cancer has metastasized to other parts of the body. Even with the recent approval of several biological therapies for the treatment of advanced metastatic RCC (VEGF inhibitors, sunitinib and sorafenib, and mTOR inhibitors everolimus and temsirolimus), the National Cancer Institute reports a rising incidence of RCC with incidence and mortality rates more than twice as high in men as in women. In 2009, an estimated 49,000 new cases of RCC and 11,000 deaths attributable to RCC are expected in the US.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in pa
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, received official ... company has been granted another key patent supporting ... This newly issued patent, European patent No. 2087002, ... drug substance in Lpath,s two lead compounds, iSONEP ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... for Caring, is a 4-Star Sponsor of Operation ... Veterans with unique products, programs and services to assist ... freedom. Key Facts: , An ... is a safe and effective treatment for pain, Post-traumatic ...
(Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... 3 Despite the pop in the shares of Dendreon ... been approved by the FDA, the biotech sector failed to build ... month with the Burrill Biotech Select Index dropping 2 percent in ... including Amgen and Gilead Sciences cut their profit forecasts citing the ...
... , , ... Bowel Control and Prevent Clinical Complications for People With,Stomas. , , ... GI, located in the Misgav Venture Accelerator, has reported,encouraging interim results in its animal trials of the ... , , ...
Cached Medicine Technology:Biotech Posts Weak Performance in April 2Biotech Posts Weak Performance in April 3Biotech Posts Weak Performance in April 4Stimatix GI Reports Encouraging Interim Results 2
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... be introduced in the U.S., has a lot to celebrate ... when our country recognizes the achievements and contributions of Americans ... the anniversary for Punzoné, and today it shares its favorite ... take a trip to Italy - even if it is ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury ... the greater Phoenix area and across Arizona reports record ... catastrophic automobile accidents. Statistics have indicated a steady increase ... As such, Hastings and Hastings has seen a steady ... who have been injured through no fault of their ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
(Date:10/19/2014)... October 20, 2014 Recently, Top10BestSEOHosting.com ... announced that JustHost, GoDaddy and HostMonster are the ... VPS (Virtual Private Server) is the method of ... each of which has the appearance and capabilities ... is why the site pays close attention to ...
(Date:10/19/2014)... October 19, 2014 Visual Impact ... has just been released to the public generating ... body building and fitness community. The commotion surrounding ... DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative review. , ... hitting what is commonly known as a training ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... , NEW YORK (March 16, 2011) -- On March ... the 2nd World Congress on Interventional Therapies for Type ... surgery as a treatment option. The three-day meeting, hosted ... City, will bring together physicians, scientists and policymakers representing ...
... organized follow-up care for depression effectively and efficiently, according ... patients that the Journal of General Internal Medicine ... five months, compared to the half of the patients ... had three online care management contacts with a trained ...
... News) -- Newly proposed national standards for mercury, arsenic ... prevent as many as 17,000 premature deaths and 11,000 ... Protection Agency. The proposed standards, released Wednesday by ... also prevent 120,000 cases of childhood asthma symptoms and ...
... This release is available in French . ... projects on regenerative medicine and nanomedicine received $16 million in ... Research (CIHR) and the Canadian Space Agency (CSA), were announced ... Member of Parliament for Oshawa; Dr. Jane Aubin, Scientific Director ...
... By Maureen Salamon HealthDay Reporter , ... be wise to avoid chatting on cell phones while ... more risky for that age group than for college ... Illinois, 18 older adults aged 59 to 81 and ...
... -- Children and adolescents growing up with inflammatory bowel disease ... by researchers at McMaster University and the McMaster Children,s Hospital. ... online, shows children and youth with the most common ... per cent lower than other children their age, and their ...
Cached Medicine News:Health News:Diabetes Surgery 2nd World Congress 2Health News:Diabetes Surgery 2nd World Congress 3Health News:Diabetes Surgery 2nd World Congress 4Health News:Diabetes Surgery 2nd World Congress 5Health News:Online messaging delivers follow-up care for depression 2Health News:EPA Proposes Tougher Air Pollution Rules for Power Plants 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 3Health News:Crossing Street While on Cell Phone Risky for Seniors 2Health News:Youth with IBD are less fit than their peers: McMaster study 2
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Medicine POLYSORB Meniscal Stapler XLS consists of ... legs of the staple. The staple is ... the meniscus. The staple is made of ... lactic acid and glycolic acids. Polylactic/polyglycolic acid ...
Medicine Products: